<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263390</url>
  </required_header>
  <id_info>
    <org_study_id>170097</org_study_id>
    <nct_id>NCT03263390</nct_id>
  </id_info>
  <brief_title>Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells</brief_title>
  <official_title>Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dina Faddah, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Gage, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to characterize the neurological basis of obesity and response to surgical
      and medical treatment by inducing adult pluripotent stem cells into neuronal cells from
      subjects that have demonstrated extreme response to bariatric surgery or pharmacological
      treatment for obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will consent subjects who have achieved extreme response to either
      bariatric surgery or pharmacologic treatment for obesity and harvest fibroblasts from skin
      biopsies, which will be reprogrammed to induced pluripotent stem cells (iPSC). These iPSC's
      will then be differentiated into neural progenitor cells, neurons, astrocytes, and microglia
      to identify genetic and epigenetic pathways altered in disease-specific neural progenitor
      cells of the brain.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DNA sequencing</measure>
    <time_frame>4 months</time_frame>
    <description>Perform DNA sequencing from skin biopsy progenitor cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Generate human cell based models of obesity</measure>
    <time_frame>4 months</time_frame>
    <description>Fibroblasts will be expanded in culture and then reprogrammed to hiPSCs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differentiation to human CNS cells</measure>
    <time_frame>4 months</time_frame>
    <description>Disease specific hiPSCs cells will be differentiated into neural progenitor cells, neurons, astrocytes, and microglia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of genetic and epigenetic pathways</measure>
    <time_frame>4 months</time_frame>
    <description>Identify genetic and epigenetic pathways altered in disease-specific neural progenitor cells, neurons, and non-neuronal cells of the brain</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Bariatric Surgery</arm_group_label>
    <description>Subjects that have demonstrated extreme response to bariatric surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti Obesity Medications</arm_group_label>
    <description>Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric Surgery</intervention_name>
    <description>Sleeve gastrectomy or Roux-en-Y Gastric Bypass</description>
    <arm_group_label>Bariatric Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti Obesity Drugs</intervention_name>
    <description>Response to FDA approved anti obesity medications</description>
    <arm_group_label>Anti Obesity Medications</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fibroblasts, iPSCs, and DNA sequencing information generated from skin biopsies will be
      expanded and stored for potential future use.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with obesity who are considered super responders to bariatric surgery or anti
        obesity pharmacotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of obesity

          -  Treatment with bariatric surgery

          -  Treatment with anti obesity medications

          -  Greater than 70% excess weight loss at least 6 months after surgery

          -  Greater than 15% weight loss on anti obesity medications

        Exclusion Criteria:

          -  Active cancer, not including non-melanoma skin cancer

          -  Active eating disorder

          -  Use of anti obesity medications in subjects with a history of bariatric surgery

          -  Active complication of the upper GI tract in patients with a history of bariatric
             surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Grunvald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Grunvald, MD</last_name>
    <phone>6197427979</phone>
    <email>egrunvald@ucsd.edu</email>
  </overall_contact>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>August 27, 2017</last_update_submitted>
  <last_update_submitted_qc>August 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Eduardo Grunvald</investigator_full_name>
    <investigator_title>Clinical Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Anti Obesity Medications</keyword>
  <keyword>Weight Regulation</keyword>
  <keyword>Pluripotent Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Obesity Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not an intervention trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

